Symptoms and patient-reported well-being: do they predict survival in malignant pleural mesothelioma? A prognostic factor analysis of EORTC-NCIC 08983: randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma.

@article{Bottomley2007SymptomsAP,
  title={Symptoms and patient-reported well-being: do they predict survival in malignant pleural mesothelioma? A prognostic factor analysis of EORTC-NCIC 08983: randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma.},
  author={Andrew Bottomley and Corneel Coens and Fabio Efficace and Rabab Mohamed Gaafar and Christian Manegold and Sjaak Burgers and Mark S. Vincent and Catherine Legrand and Jan P. van Meerbeeck},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2007},
  volume={25 36},
  pages={
          5770-6
        }
}
PURPOSE Malignant pleural mesothelioma (MPM) is a rare disease. Unlike other advanced cancer types, little is known about patient-reported symptoms or health-related quality of life (HRQOL) and their possible prognostic value. This study reports an evaluation of the prognostic value of these factors using data gathered from a recent randomized controlled trial. PATIENTS AND METHODS Patients were entered onto this trial if they had a histologically proven unresectable MPM, not pretreated with… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 34 CITATIONS, ESTIMATED 50% COVERAGE

69 Citations

051015'10'12'14'16'18
Citations per Year
Semantic Scholar estimates that this publication has 69 citations based on the available data.

See our FAQ for additional information.

Similar Papers

Loading similar papers…